
Real-world data from nearly 2,900 patients show that benralizumab significantly reduced both asthma and COPD exacerbations in individuals with asthma and concomitant COPD. The greatest benefits were seen in patients with elevated eosinophil counts, alongside reduced reliance on systemic corticosteroids.
Like
Save
Share